Earnings

Amgen Reports First Quarter 2017 Financial Results

View printer-friendly version Amgen Reports First Quarter 2017 Financial Results BUZ INVESTORS  PRESS RELEASE  Amgen Reports First Quarter Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include: Total revenues decreased 1 percent versus the first quarter of 2016 to $5.5 billion. GAAP earnings per share (EPS) increased 12 percent to […]

BUZ INVESTORS PRESS RELEASE Whirlpool Corporation (WHR) (NYSE: WHR) announced today first-quarter GAAP net earnings of $153 million,
Market Trends

Whirlpool Corporation Reports First-Quarter 2017 Results And Revises Full-Year Guidance

Whirlpool Corporation Reports First-Quarter 2017 Results And Revises Full-Year Guidance BUZ INVESTORS PRESS RELEASE  Whirlpool Corporation (WHR) (NYSE: WHR) announced today first-quarter GAAP net earnings of $153 million, or $2.01 per diluted share, compared to $150 million, or $1.92 per diluted share, reported for the same prior-year period. First-quarter ongoing business earnings per diluted share(1) […]

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS
Market Trends

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS Company grew profits sequentially on stronger alumina and aluminum pricing BUZ INVESTORS PRESS RELEASE Alcoa Corporation (NYSE: AA): 1Q 2017 Results1 Net income of $225 million, or $1.21 per share Excluding special items, adjusted net income of $117 million, or $0.63 per share Adjusted earnings before interest, tax, depreciation, […]

BUZ INVESTORS First Quarter 2017 Halliburton Company (HAL) announced today a loss from continuing operations of $32 million, or $0.04 per diluted share,
Market Trends

Halliburton Announces First Quarter 2017 Results

Halliburton Announces First Quarter 2017 Results Reported loss from continuing operations of $0.04 per diluted share Adjusted income from continuing operations of $0.04 per diluted share, excluding costs related to an early extinguishment of debt BUZ INVESTORS Halliburton First Quarter 2017  Halliburton Company (HAL) announced today a loss from continuing operations of $32 million, or $0.04 per diluted […]

BUZ INVESTORS Mattel shares fall 7% Mattel, Inc. (Nasdaq: MAT) today announced that it plans to release its first quarter 2017 financial results on Thursday, April 20, 2017,
Market Trends

Mattel shares fall 7% after quarterly results miss estimates

MATTEL ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL BUZ INVESTORS  Mattel shares fall 7% Mattel, Inc. (Nasdaq: MAT) today announced that it plans to release its first quarter 2017 financial results on Thursday, April 20, 2017, at approximately 4:05 p.m. Eastern time. Following this, Margo Georgiadis, Chief Executive Officer; Richard Dickson, President and Chief Operating Officer; and Kevin Farr, Chief Financial Officer […]

BUZ INVESTORS Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids
Market Trends

$VBIO Announces Positive Results for Colon Cancer

Vitality Biopharma Announces Positive Results for Colon Cancer Cannabidiol inhibits the growth of colon cancer cell lines, highlights new use for targeted cannabinoid prodrug delivery system BUZ INVESTORS Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for […]

Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016
Market Trends

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE Download PDF COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 23, 2017 AT 10:00 AM EDT Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016   — Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for […]